Effect of perioperative blood transfusions on long term graft outcomes in renal transplant patients
Department of Nephrology, Beaumont Hospital, Dublin, Ireland. Clinical nephrology
(Impact Factor: 1.13).
06/2012; 77(6):432-7. DOI: 10.5414/CN107436
It is established that blood transfusions will promote sensitization to human leucocyte antigen (HLA) antigens, increase time spent waiting for transplantation and may lead to higher rates of rejection. Less is known about how perioperative blood transfusion influence patient and graft outcome. This study aims to establish if there is an association between perioperative blood transfusion and graft or patient survival.
This was a single center, national, retrospective cohort study. Data was collected on patients who received kidney transplants over a 14-year period (n = 2,013). The primary outcomes were graft survival and mortality in patients who received blood transfusions in the perioperative period compared to those who did not.
Patients who received blood transfusions had lower hemoglobin levels, were more likely to be male, and had higher rates of delayed graft function compared to those who did not receive a transfusion. The one year graft survival of those transfused was 83% compared to 94% in those not transfused (p = < 0.0001). Adjustment for confounding showed that the receipt of a blood transfusion remained associated with increased graft loss. Hemoglobin levels prior to transfusion did not have an influence on graft outcome.
Perioperative blood transfusion is associated with reduced long-term graft survival.
Available from: Samantha Fidler
- "This effect of peri-operative transfusion was not found in recipients without DSA, suggesting that the combination of DSA and peri-operative blood transfusion may be particularly detrimental to the transplanted graft. Importantly , adverse events after peri-operative blood transfusion included not only antibody mediated rejection, but also poorer long term graft outcome and recipient death, independent of the risk of AMR and Non-AMR, consistent with the findings of O'Brien et al. . "
[Show abstract] [Hide abstract]
ABSTRACT: Historic Red Blood Cell Transfusion (RBCT) may induce anti-HLA antibody which if donor specific (DSA), is associated with increased antibody-mediated rejection (AMR). Whether post-operative RBCT influences this risk is unknown. We examined the RBCT history in 258 renal transplant recipients stratified according to prevalent recipient HLA antibody (DSA, Non-DSA or No Antibody). AMR occurred more frequently in patients who received RBCT both pre and post transplant compared with all other groups (Pre+Post-RBCT 21%, Pre-RBCT 4%, Post-RBCT 6%, No-RBCT 6%, HR 4.1 p=0.004). In the 63 patients who received Pre+Post-RBCT, 65% (13/20) with DSA developed AMR compared with 0/6 in the non-DSA group and 2/37 (5%) in the No-Antibody group (HR 13.9 p<0.001). In patients who received No-RBCT, Pre-RBCT or Post-RBCT there was no difference in AMR between patients with DSA, Non-DSA or No-Antibody. Graft loss was independently associated with Pre+Post-RBCT (HR 6.5, p=0.001) AMR (HR 23.9 p<0.001) and Non-AMR (6.0 p=0.003) after adjusting for DSA and delayed graft function. Re-exposure to RBCT at the time of transplant is associated with increased AMR only in patients with preformed DSA, suggesting RBCT provides additional allostimulation . Patients receiving pre+post-RBCT also had an increased risk of graft loss independently of AMR or DSA. Both pre and post procedural RBCT in renal transplantation is associated with modification of immunological risk and warrants additional study.
Transplant Immunology 09/2013; 29(1-4). DOI:10.1016/j.trim.2013.09.008 · 1.46 Impact Factor
Available from: Joseph G Lawen
- "The effects of blood transfusion on new HLA antibody formation appears to be low in the short term . However the cumulative effect of transfusions may compromise outcomes in those needing a repeat transplant . "
[Show abstract] [Hide abstract]
Given the unpredictable timing of deceased donor organs and the need for blood transfusion, this study was carried out to determine the rate and risk factors for transfusion in order to identifying a low-risk cohort in the face of a critical blood shortage.
This retrospective chart review examined 306 consecutive deceased solitary kidney transplant recipients from January 2006 to August 2012.
Records show that 80 (26.1%) patients were transfused with a total of 300 units (0.98 units/transplant) during their first hospital stay. Transfusions were higher in patients on warfarin (8/14, 57%, 5.1 units/transplant) and antiplatelet agents (46/136, 33.8%, 1.1 unit/transplant) compared to no anticoagulants (74/156, 16.7%, 0.47 units/transplant). In a multivariable logistic regression analysis warfarin (odd ratio (OR) 8.2, 95% confidence interval (CI) 2.5–27, P=0.001), antiplatelet agents (OR 2.9, 95% CI 1.6–5.3, P=0.001), recipient age ≥55 years (OR 2.2, 95% CI 1.2–3.9, P=0.008), recipient male (OR 0.36, 95% CI 0.2–0.64, P=0.001) and preop hemoglobin ≥115 g/L (OR 0.32, 95% CI 0.18–0.57, P<0.001) were independent predictors of blood transfusion. Lower bleeding cohorts with transfusion rates <5% could not be identified.
The need for blood is significantly higher in subjects on either warfarin or antiplatelet agents. These patients might be avoided if kidney transplantation is to occur during a critical blood shortage. Unfortunately even patients not on anticoagulation are at some risk.
04/2013; 2(1):4. DOI:10.1186/2047-1440-2-4
[Show abstract] [Hide abstract]
ABSTRACT: Virtual Panel Reactive Antibodies (vPRA) has been implemented to gauge sensitization worldwide. It is unclear how it associates with long-term outcomes, and its correlation with peak (pPRA) or actual (aPRA) has not been studied. We retrospectively reviewed data from 18-65 year-old kidney-only transplant patients during 1.1.1996-31.7.2011 in our centre. PRAs were calculated based on solid-phase techniques. Of the 726 qualified cases, regardless of the PRA type, sensitized patients (PRA>5%) had more females and previous transplant. Highly sensitized (HS, PRA>50%) had longer waiting time, lower transplant rate, less living donor, more delayed graft function and acute rejection. The conformity between vPRA and pPRA in HS were 75%, 57% between pPRA and aPRA. Forty-three percent (61/142) patients whose pPRA was >5% had no detectable aPRA and maintained similar outcomes as sensitized patients. Multivariate analysis showed consistently lower death-censored graft survival in HS defined by vPRA [HR 2.086 (95% CI 1.078-4.037), P<0.05] and pPRA [HR 2.139 (95% CI 1.024-4.487), P<0.05]. Both vPRA and pPRA provided reliable way estimating sensitization and predicting long-term graft survival, while aPRA might underestimate true sensitization. vPRA might be the most objective parameter to gauge sensitization. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
Transplantation 11/2012; 94(10S):1076. DOI:10.1097/00007890-201211271-02132 · 3.83 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.